| Anti-PD-L1 efficacy can be enhanced by inhibition of myeloid-derived suppressor cells with a selective inhibitor of PI3Kδ/γ RJ Davis, EC Moore, PE Clavijo, J Friedman, H Cash, Z Chen, C Silvin, ... Cancer research 77 (10), 2607-2619, 2017 | 204 | 2017 |
| Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy L Sun, PE Clavijo, Y Robbins, P Patel, J Friedman, S Greene, R Das, ... JCI insight 4 (7), 2019 | 198 | 2019 |
| Inhibition of MDSC trafficking with SX-682, a CXCR1/2 inhibitor, enhances NK-cell immunotherapy in head and neck cancer models S Greene, Y Robbins, WK Mydlarz, AP Huynh, NC Schmitt, J Friedman, ... Clinical Cancer Research 26 (6), 1420-1431, 2020 | 183 | 2020 |
| Established T cell–inflamed tumors rejected after adaptive resistance was reversed by combination STING activation and PD-1 pathway blockade E Moore, PE Clavijo, R Davis, H Cash, C Van Waes, Y Kim, C Allen Cancer immunology research 4 (12), 1061-1071, 2016 | 134 | 2016 |
| Host immunity following near-infrared photoimmunotherapy is enhanced with PD-1 checkpoint blockade to eradicate established antigenic tumors T Nagaya, J Friedman, Y Maruoka, F Ogata, S Okuyama, PE Clavijo, ... Cancer immunology research 7 (3), 401-413, 2019 | 120 | 2019 |
| PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation M Morisada, PE Clavijo, E Moore, L Sun, M Chamberlin, C Van Waes, ... Oncoimmunology 7 (3), e1395996, 2018 | 107 | 2018 |
| Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells PE Clavijo, EC Moore, J Chen, RJ Davis, J Friedman, Y Kim, C Van Waes, ... Oncotarget 8 (34), 55804, 2017 | 88 | 2017 |
| Integrated genomic and functional microRNA analysis identifies miR-30-5p as a tumor suppressor and potential therapeutic nanomedicine in head and neck cancer AD Saleh, H Cheng, SE Martin, H Si, P Ormanoglu, S Carlson, PE Clavijo, ... Clinical Cancer Research 25 (9), 2860-2873, 2019 | 80 | 2019 |
| Anti-tumor immunity in head and neck cancer: understanding the evidence, how tumors escape and immunotherapeutic approaches CT Allen, PE Clavijo, C Van Waes, Z Chen Cancers 7 (4), 2397-2414, 2015 | 65 | 2015 |
| Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types KC Hicks, M Fantini, RN Donahue, A Schwab, KM Knudson, SR Tritsch, ... Oncoimmunology 7 (11), e1466018, 2018 | 63 | 2018 |
| Neoadjuvant PD-1 immune checkpoint blockade reverses functional immunodominance among tumor antigen–specific T cells J Friedman, EC Moore, P Zolkind, Y Robbins, PE Clavijo, L Sun, ... Clinical Cancer Research 26 (3), 679-689, 2020 | 62 | 2020 |
| Semaphorin4D inhibition improves response to immune-checkpoint blockade via attenuation of MDSC recruitment and function PE Clavijo, J Friedman, Y Robbins, EC Moore, E Smith, M Zauderer, ... Cancer immunology research 7 (2), 282-291, 2019 | 54 | 2019 |
| WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy L Sun, E Moore, R Berman, PE Clavijo, A Saleh, Z Chen, C Van Waes, ... Oncoimmunology 7 (10), e1488359, 2018 | 47 | 2018 |
| Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis CT Allen, S Lee, SM Norberg, D Kovalovsky, H Ye, PE Clavijo, ... Journal for immunotherapy of cancer 7, 1-9, 2019 | 45 | 2019 |
| Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition P Patel, L Sun, Y Robbins, PE Clavijo, J Friedman, C Silvin, C Van Waes, ... Oncoimmunology 8 (11), e1638207, 2019 | 45 | 2019 |
| Anergic CD8+ T lymphocytes have impaired NF-κB activation with defects in p65 phosphorylation and acetylation PE Clavijo, KA Frauwirth The Journal of Immunology 188 (3), 1213-1221, 2012 | 43 | 2012 |
| ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and … W Ye, S Gunti, CT Allen, Y Hong, PE Clavijo, C Van Waes, NC Schmitt Oncoimmunology 9 (1), 1710398, 2020 | 37 | 2020 |
| Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells Y Robbins, S Greene, J Friedman, PE Clavijo, C Van Waes, KP Fabian, ... Elife 9, e54854, 2020 | 36 | 2020 |
| Attenuated TRAF3 fosters activation of alternative NF-κB and reduced expression of antiviral interferon, TP53, and RB to promote HPV-positive head and neck cancers J Zhang, T Chen, X Yang, H Cheng, SS Späth, PE Clavijo, J Chen, ... Cancer research 78 (16), 4613-4626, 2018 | 34 | 2018 |
| Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms EC Moore, L Sun, PE Clavijo, J Friedman, JB Harford, AD Saleh, ... Oncoimmunology 7 (7), e1404216, 2018 | 29 | 2018 |
